Alcoholic Hepatitis Therapeutics Market Size, Share, Growth, Forecast Report 2022-2030

According to Latest Report Study, the global alcoholic hepatitis therapeutics market size was valued at US$ 0.7 billion in 2021 and is expected to reach US$ 1.3 billion by 2030 expanding at a CAGR of 6% from 2022 to 2030.

The market growth can be primarily attributed to the high prevalence of alcohol-related diseases worldwide, emphasis on the development of new therapies, and consistent growth in the number of research and development projects, among others.

Immediate Delivery Available | Get the sample copy of report@ https://www.visionresearchreports.com/report/sample/37112

Alcoholic hepatitis is a liver infection caused due to frequent and high consumption of alcohol. Fat that builds up in liver cells can lead to inflammation and scarring of the liver. The infection can be mild or severe. A patient may need a liver transplant if he does not receive treatment or stop consuming alcohol during the early stages. Different types of therapeutics are used in the treatment of alcoholic hepatitis, including corticosteroids, hemorrheologic agents, and anabolic steroids. The growth of the global alcoholic hepatitis therapeutics market can be ascribed to increase in prevalence of the alcoholic liver disease and rise in rate of consumption of alcohol across the globe.

North America dominated the global alcoholic hepatitis therapeutics market in 2020. This trend is anticipated to continue during the forecast period. Highly structured healthcare industry, early new product adoption, high prevalence rate of alcoholic hepatitis, and presence of major players are estimated to drive the alcoholic hepatitis therapeutics market in North America. Asia Pacific is likely to be a highly lucrative region of the global alcoholic hepatitis therapeutics market. It is projected to expand at a fast-paced CAGR during the forecast period.

Scope of The Report

Increase in Prevalence of Alcoholic Liver Disease and Rise in Alcohol Consumption Rate to Drive Global Market

Increase in the number of patients afflicted with the alcoholic liver disease across the globe is a key factor driving the global alcoholic hepatitis therapeutics market. Around 88,000 people succumb to alcohol-related diseases annually, making alcohol the fourth leading preventable cause of death in the U.S. Rise in the rate of consumption of alcohol across the globe, especially in developed countries such as the U.S., is expected to boost the market in the near future. The use of alcohol varies throughout the world; the U.S. and Europe record the highest usage of alcohol. Around 67.3% of the population in the U.S. consumes alcohol in the U.S; of this, 7.4% meets the criteria for alcohol abuse.

Strong product pipeline is also anticipated to propel the global alcoholic hepatitis therapeutics market during the forecast period. For instance, Generon Pharmaceutical Technology (Shanghai) Co., Ltd. has an innovative product, F-652, in phase 2 of clinical trial.

Research Activities Likely to Stall amid COVID-19 Pandemic, Drug Development to Continue

The advent of the novel COVID-19 pandemic has played a critical role in influencing the overall operations across the healthcare sector. While the pressure remains high to discover a vaccine or drug to treat the novel coronavirus, research activities pertaining to the development of alcoholic hepatitis therapeutics are likely to take a hit amid the ongoing health crisis. Investments are likely to delay along with potential delays in the development of new drugs and therapies. While the market in the first quarter of 2020 was largely affected by the lockdown imposed by the Chinese Government, the second and third quarters are expected to witness considerable bottlenecks across the supply chain due to restrictions on cross-border trade and transportation.

The global alcoholic hepatitis therapeutics market is expected to witness slower growth compared to the growth in 2020. However, as governments around the world gradually ease down lockdown regulations, the alcoholic hepatitis therapeutics market is likely to witness considerable activity toward the last quarter of 2020.

Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/37112

Corticosteroids Treatment to Dominate Alcoholic Hepatitis Therapeutics Market

Based on treatment, the global alcoholic hepatitis therapeutics market has been divided into corticosteroids, hemorrheologic agents, anabolic steroids, and others. The corticosteroids segment dominated the global alcoholic hepatitis therapeutics market in 2020. This trend is projected to continue during the forecast period. Corticosteroids are considered the first line of treatment in the management of alcoholic hepatitis. Thus, the segment accounts for significant share of the global alcoholic hepatitis therapeutics market.

Corticosteroids was followed by the hemorrheologic agents segment in terms of market share in 2020. Various clinical trials are being conducted to establish the efficacy of pentoxifylline in managing severe alcoholic hepatitis. This is augmenting the hemorrheologic agents segment.

Mild to be Highly Lucrative Application Area of Alcoholic Hepatitis Therapeutics Market

In terms of application, the global alcoholic hepatitis therapeutics market has been bifurcated into mild and severe/chronic. The mild segment accounted for a prominent share of the global alcoholic hepatitis therapeutics market in 2020, owing to rise in awareness about the ill effects of alcohol and early diagnosis of the disease.

Hospital Pharmacies to be Major Distribution Channel

In terms of distribution channel, the global alcoholic hepatitis therapeutics market has been classified into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment led the global alcoholic hepatitis therapeutics market in terms of revenue in 2020. The trend is expected to continue during the forecast period. Rapid increase in the number of hospitals and a wide range of services available in multispecialty hospitals are likely to boost the segment during the forecast period. Rise in the number of patients opting for retail pharmacies, due to a large number of product brands available at discounted prices at these pharmacies, is estimated to drive the retail pharmacies segment during the forecast period.

North America to Dominate Alcoholic Hepatitis Therapeutics Market

In terms of region, the global alcoholic hepatitis therapeutics market has been divided into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global alcoholic hepatitis therapeutics market in 2020. It was followed by Europe. Significant share of North America can be ascribed to the increase in the number of people with alcoholic hepatitis, new product launches, and presence of major players in the region. Furthermore, high consumption of alcohol, poor diet, and obesity are some of the common factors boosting the market in the region.

The alcoholic hepatitis therapeutics market in Asia Pacific is anticipated to expand at a fast-paced CAGR from 2021 to 2030. This can be ascribed to the presence of developing economies with commercial hubs, expanding business organizations, growing awareness about alcoholic hepatitis, improving health care infrastructure, and rising investments by companies in their technical aspects.

Market Trend

The development of combination therapies to treat severe alcoholic hepatitis is a major trend influencing the alcoholic hepatitis treatment market growth. The market has witnessed the development of combination therapies to treat severe alcoholic hepatitis. Currently, there is no effective treatment for severe alcoholic hepatitis. Therefore, researchers are focusing on developing combination therapies, as they are more effective. For instance, the researchers at the University of Massachusetts Medical School are studying a combination therapy with Kineret, Trental, and zinc sulfate. During the multicenter study, the combination showed short- and long-term survival benefits in patients with severe alcoholic hepatitis with no unexpected treatment-related severe adverse events. Similarly, Gilead Sciences is conducting a Phase II clinical trial to evaluate the safety and tolerability of selonsertib (GS-4997) in combination with prednisolone in patients with severe alcoholic hepatitis. Furthermore, researchers are evaluating an antibiotic combined with a corticosteroid by targeting the group of patients at high risk of death due to alcoholic hepatitis. Also, researchers are conducting a study on N-acetylcysteine and prednisolone combination therapy for people with severe alcoholic hepatitis in order to improve short-term mortality. Such developments of combination therapies are expected to drive the growth of the market during the forecast period.

Market Challenge

The lack of therapies to treat severe alcoholic hepatitis is a major hindrance to the alcoholic hepatitis treatment market growth. There is a lack of therapies to treat severe alcoholic hepatitis, which may pose a challenge to market growth. Only corticosteroids are the main treatment options for severe alcoholic hepatitis. However, several patients have contraindications for steroid treatment. According to Behnam Saberi et al., there is no clear evidence that steroids are effective in the management of alcoholic hepatitis. Corticosteroids are recommended by the American Association for the Study of Liver Disease and the European Association for the Study of Liver as first-line therapy for severe alcoholic hepatitis. However, corticosteroids are associated with several contraindications such as renal failure, active gastrointestinal bleeding, uncontrolled hyperglycemia, and acute pancreatitis. Similarly, pentoxifylline is recommended for people with severe alcoholic hepatitis, if they have contraindications to corticosteroids. However, pentoxifylline has no impact on disease progression. Similarly, etanercept was evaluated in a multicenter study by Boetticher et al. According to the results, the six-month mortality was high in patients treated with etanercept. Also, serious adverse events were significantly high in patients. Another monoclonal antibody, infliximab, in a multicenter study, showed that the probability of death at two months was high in patients. These factors are expected to hinder the growth of the global alcoholic hepatitis treatment market during the forecast period.

This alcoholic hepatitis treatment market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2022-2030.

Competition Landscape

The global alcoholic hepatitis therapeutics market is fragmented in terms of number of players. Key players operating in the global market include Gilead Sciences, Inc., Sanofi, Generon Pharmaceutical Technology (Shanghai) Co., Ltd., Immuron Ltd., and Intercept Pharmaceuticals, Inc.

Market Segmentation

By Treatment

• Corticosteroids
• Hemorrheologic Agents
• Anabolic Steroids
• Others (tumor necrosis factor-α (TNF-α) inhibitors, antioxidants, etc.)

By Application

• Mild
• Severe/Chronic

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/37112

You can place an order or ask any questions, please feel free to contact at sales@visionresearchreports.com | +1 9197 992 333

Blog: https://www.novaoneadvisor.com/

Blog: https://qyresearchmedical.com/